Decheng Capital LLC Nuvation Bio Inc. Transaction History
Decheng Capital LLC
- $466 Billion
- Q4 2024
A detailed history of Decheng Capital LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Decheng Capital LLC holds 25,954,439 shares of NUVB stock, worth $47.2 Million. This represents 14.81% of its overall portfolio holdings.
Number of Shares
25,954,439
Previous 25,954,439
-0.0%
Holding current value
$47.2 Million
Previous $59.4 Billion
16.16%
% of portfolio
14.81%
Previous 14.08%
Shares
2 transactions
Others Institutions Holding NUVB
# of Institutions
163Shares Held
151MCall Options Held
1.2KPut Options Held
223K-
Black Rock Inc. New York, NY16.2MShares$29.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.7MShares$28.6 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$23.8 Million53.05% of portfolio
-
Octagon Capital Advisors LP New York, NY9.2MShares$16.7 Million5.46% of portfolio
-
Laurion Capital Management LP New York, NY6.49MShares$11.8 Million0.33% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $395M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...